Inflammatory resolution: new opportunities for drug discovery.
Gilroy
Derek W
DW
William Harvey Research Institute, St. Bartholomew's and the Royal London School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK. d.w.gilroy@qmul.ac.uk
Lawrence
Toby
T
Perretti
Mauro
M
Rossi
Adriano G
AG
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D016718:Arachidonic Acid / Q000378:metabolism* / Q000502:physiology; D005938:Glucocorticoids / Q000494:pharmacology / Q000627:therapeutic use*; D006634:Histamine H1 Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D044045:Lipoxins / Q000378:metabolism / Q000502:physiology; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005938:Glucocorticoids; D006634:Histamine H1 Antagonists; D044045:Lipoxins; D016328:NF-kappa B; D016718:Arachidonic Acid